||Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 540 active entries
One Research Way
Princeton, NJ 08540, USA
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
The Liposome Company, Inc. (Nasdaq: LIPO) develops, manufactures and markets liposome- and lipid-based pharmaceuticals for the treatment of cancer and other life-threatening diseases. ABELCET(R) has been approved for sale in the U.S. and 19 other countries for the treatment of severe, systemic fungal infections. The Company has a pipeline of oncology products including EVACET(TM), in Phase III testing for the treatment of metastatic breast cancer. TLC ELL-12 and other oncology products are in earlier stages of development.
Last update of this entry: before October 1999.